In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 1.61 below Invitae Corporation average.

Within Medical Laboratories industry 19 other companies have achieved higher Quick Ratio than Invitae in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 1169, from total ranking in the second quarter 2023 at 1874.

Explain Quick Ratio?
How much Cash & cash equivalents NVTA�s has?
What are NVTA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVTA Quick Ratio	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3
Y / Y Current Liabilities Change	39.8 %	9.13 %	13.27 %	-24.98 %	-27.44 %
Y / Y Cash & cash equivalent Change	-56.55 %	-55.26 %	-56.71 %	-47.66 %	-52.82 %
Quick Ratio MRQ	1.61	2.14	1.99	5.06	5.17
NVTA's Total Ranking	# 1169	# 1874	# 1206	# 703	# 788
Seq. Current Liabilities Change	4.24 %	-20.09 %	75.94 %	-4.61 %	-18.62 %
Seq. Cash & cash equivalent Change	-21.7 %	-14.14 %	-30.78 %	-6.63 %	-19.37 %

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Medical Laboratories Industry	# 20
Healthcare Sector	# 553
Overall Market	# 1169

Quick Ratio Statistics
High	Average	Low
19.1	6.1	1.56
(Mar 31 2015)		(Mar 31 2018)

Financial Statements
Invitae's Current Liabilities	$ 158 Millions	Visit NVTA's Balance sheet
Invitae's Cash & cash equivalent	$ 255 Millions	Visit NVTA's Balance sheet
Source of NVTA's Sales		Visit NVTA's Sales by Geography

Cumulative Invitae's Quick Ratio

NVTA's Quick Ratio for the trailling 12 Months

NVTA Quick Ratio	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	7.81 %	-7.22 %	-8.47 %	-8.82 %	1.3 %
Y / Y Cash & cash equivalent TTM Growth	-53.43 %	-52.77 %	-52.29 %	-39.09 %	-14.88 %
Quick Ratio TTM	2.47	3.26	4.06	5.17	5.73
Total Ranking TTM	# 3750	# 2962	# 3646	# 3921	# 3527
Seq. Current Liabilities TTM Growth	8 %	2.31 %	4.22 %	-6.38 %	-7.05 %
Seq. Cash & cash equivalent TTM Growth	-18.04 %	-17.94 %	-18.14 %	-15.41 %	-16.87 %

Quick ratio ranking by company, industry and sector >> Back to NVTA Financial Strength Comparisons >> Go to Compare NVTA Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2023 to $158.42 millions, cumulative Quick Ratio decreased to 2.47 below the Invitae Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 42 other companies have achieved higher Quick Ratio than Invitae. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2962 to 3750.

Explain Quick Ratio?
How much Cash & cash equivalents NVTA�s has?
What are NVTA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 43
Healthcare Sector	# 1043
Within the Market	# 3750

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.43	4.68	2.07
(Dec 31 2016)		(Jun 30 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Medical Laboratories Industry	Quick Ratio	Sep 30 2023 MRQ Cash & cash equivalent	Sep 30 2023 MRQ Current Liabilities
Veracyte Inc	4.05	$ 202.463 Millions	$ 50.039 Millions
Bionexus Gene Lab Corp	3.82	$ 6.147 Millions	$ 1.610 Millions
Science 37 Holdings Inc	3.76	$ 56.407 Millions	$ 15.020 Millions
Personalis Inc	3.72	$ 120.663 Millions	$ 32.478 Millions
Caredx Inc	3.69	$ 268.184 Millions	$ 72.674 Millions
Sera Prognostics Inc	3.40	$ 46.116 Millions	$ 13.545 Millions
Exagen Inc	3.17	$ 28.448 Millions	$ 8.981 Millions
Incyte Corporation	3.13	$ 3,516.453 Millions	$ 1,124.680 Millions
WEED, INC.	3.00	$ 0.644 Millions	$ 0.215 Millions
Hologic Inc	2.91	$ 2,722.500 Millions	$ 934.400 Millions
Absci Corp	2.81	$ 69.733 Millions	$ 24.799 Millions
Burning Rock Biotech Limited	2.43	$ 86.634 Millions	$ 35.710 Millions
Bioaffinity Technologies Inc	2.30	$ 4.509 Millions	$ 1.959 Millions
Exact Sciences Corporation	1.65	$ 734.406 Millions	$ 446.124 Millions
Ispecimen inc	1.61	$ 5.663 Millions	$ 3.517 Millions
Invitae Corporation	1.61	$ 254.573 Millions	$ 158.419 Millions
American Shared Hospital Services	1.46	$ 14.655 Millions	$ 10.049 Millions
Fulgent Genetics Inc	1.37	$ 84.076 Millions	$ 61.421 Millions
Natera Inc	1.06	$ 267.847 Millions	$ 251.705 Millions
Radnet Inc	0.96	$ 392.362 Millions	$ 407.077 Millions
Renalytix Plc	0.92	$ 13.891 Millions	$ 15.173 Millions
Biodesix Inc	0.61	$ 19.841 Millions	$ 32.649 Millions
Inotiv Inc	0.54	$ 35.492 Millions	$ 66.290 Millions
Centogene N v	0.44	$ 21.391 Millions	$ 48.570 Millions

Date modified: 2026-09-08T15:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.